CHA2DS2-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention

被引:7
|
作者
Huang, Xin [1 ]
Zheng, Wen [1 ]
Zhao, Xue Dong [1 ]
Nie, Shao Ping [1 ]
机构
[1] Capital Med Univ, Emergency & Crit Care Ctr, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing, Peoples R China
关键词
CHA(2)DS(2)-VASc score; multivessel disease; percutaneous coronary intervention; slow flow; no-reflow phenomenon; ST elevation myocardial infarction; NO-REFLOW; MICROVASCULAR DYSFUNCTION; HYPERGLYCEMIA; OBSTRUCTION; GUIDELINES; OUTCOMES;
D O I
10.1097/MD.0000000000026162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) have a higher incidence of slow-flow/no-reflow (SF-NR) phenomenon during primary percutaneous coronary intervention (PPCI) than those with single vessel disease. Currently, no effective tools exist to predict the risk of SF-NR in this population. The present study aimed to evaluate whether CHA(2)DS(2)-VASc score can be used as a simple tool to predict this risk. This study consecutively included STEMI patients hospitalized in Beijing Anzhen Hospital from January 2005 to January 2015. Among these patients, 1032 patients with MVD were finally enrolled. Patients were divided into SF-NR (+) group and SF-NR (-) group according to whether SF-NR occurred during PPCI. SF-NR was defined as the thrombolysis in myocardial infarction (TIMI) grade <= 2. There were 134 patients (13%) in the SF-NR (+) group. Compared with the SF-NR (-) group, patients in the SF-NR (+) group are elder, with lower left ventricular ejection fraction and higher CHA(2)DS(2)-VASc score. Multiple logistic regression analysis indicated that CHA(2)DS(2)-VASc score >= 3 (odds ratio [OR], 2.148; 95% confidence interval [CI], 1.389-3.320; P = .001), current smoking (OR, 1.814; 95% CI, 1.19-2.764; P = .006), atrial fibrillation (OR, 2.892; 95% CI, 1.138-7.350; P = .03), complete revascularization (OR, 2.307; 95% CI, 1.202-4.429; P = .01), and total length of stents >= 40 mm (OR, 1.482; 95% CI, 1.011-2.172; P = .04) were independent risk factors of SF-NR. The incidence of SF-NR in patients with CHA(2)DS(2)-VASc score >= 3 was 1.7 times higher than that in patients with CHA(2)DS(2)-VASc score <3. Additionally, patients with CHA(2)DS(2)-VASc score >= 3 plus >= 2 risk factors have 3 times higher incidence of SF-NR than those with CHA(2)DS(2)-VASc score >= 3 plus 0 to 1 risk factor. CHA(2)DS(2)-VASc score >= 3 can be used as a simple and sensitive indicator to predict SF-NR phenomenon and guide the PPCI strategy in STEMI patients with MVD.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention
    Ipek, Gokturk
    Onuk, Tolga
    Karatas, Mehmet B.
    Gungor, Baris
    Osken, Altug
    Keskin, Muhammed
    Oz, Ahmet
    Tanik, Ozan
    Hayiroglu, Mert Ilker
    Yaka, Hale Yilmaz
    Ozturk, Recep
    Bolca, Osman
    ANGIOLOGY, 2016, 67 (09) : 840 - 845
  • [2] New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
    Qin-Yao Zhang
    Shu-Mei Ma
    Jia-Ying Sun
    BMC Cardiovascular Disorders, 20
  • [3] New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
    Zhang, Qin-Yao
    Ma, Shu-Mei
    Sun, Jia-Ying
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)
  • [4] Comparison of RCHA2DS2-VASc score and CHA2DS2-VASc score prediction of no-reflow phenomenon in patients with ST-segment elevation myocardial infarction
    Zorlu, Cagri
    Koseoglu, Cemal
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2020, 48 (07): : 664 - 672
  • [5] CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention
    Mirbolouk, Fardin
    Gholipour, Mahboobeh
    Salari, Arsalan
    Shakiba, Maryam
    Kheyrkhah, Jalal
    Nikseresht, Vahid
    Sotoudeh, Nozar
    Moghadam, Negar
    Mirbolouk, Mohammad Jaafar
    Far, Mani Moayeri
    JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2018, 10 (01) : 46 - 52
  • [6] CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Rashed, Mohamed Ismail
    Saleh, Mohamed Ayman
    Elfekky, Ehab Mohamed
    Elmahmoudy, Ahmed Mohamed
    EGYPTIAN HEART JOURNAL, 2022, 74 (01):
  • [7] CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Mohamed Ismail Rashed
    Mohamed Ayman Saleh
    Ehab Mohamed Elfekky
    Ahmed Mohamed Elmahmoudy
    The Egyptian Heart Journal, 74
  • [8] CHA2DS2-VASc score predicts contrast induced nephropathy in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention
    Cicek, G.
    Yildirim, E.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1166 - 1166
  • [9] New R2-CHA2DS2-VASc score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention
    Zhang, Qinyao
    Hu, Meirong
    Ma, Shumei
    Niu, Tiesheng
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [10] Prognostic value of CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
    Satilmisoglu, Muhammet Hulusi
    Gul, Mehmet
    Yildiz, Gunduz
    Akgul, Ozgur
    Kaya, Mehmet
    Cakmak, Huseyin Altug
    Akkaya, Emre
    Aslan, Serkan
    Ameri, Mohammad Toib
    Ozyilmaz, Sinem Ozbay
    Yildirim, Aydin
    ACTA CARDIOLOGICA, 2016, 71 (06) : 663 - 669